Relevant bibliographies by topics / Intravenous Immunoglobulin / Journal articles

Journal articles on the topic 'Intravenous Immunoglobulin'

To see the other types of publications on this topic, follow the link: Intravenous Immunoglobulin.
Author: Grafiati
Published: 4 June 2021
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Intravenous Immunoglobulin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Besa, Emmanuel C., and Barbara A. Neilan. "Intravenous immunoglobulin." Postgraduate Medicine 86, no. 6 (November 1989): 189–95. http://dx.doi.org/10.1080/00325481.1989.11704485.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

MD, Y. G. "Intravenous immunoglobulin." Neurology 42, no. 10 (October 1, 1992): 2053. http://dx.doi.org/10.1212/wnl.42.10.2053-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wedgwood, Ralph J. "Intravenous immunoglobulin." Clinical Immunology and Immunopathology 40, no. 1 (July 1986): 147–50. http://dx.doi.org/10.1016/0090-1229(86)90079-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cowden, Jessica, and Sarah K. Parker. "Intravenous Immunoglobulin." Pediatric Infectious Disease Journal 25, no. 7 (July 2006): 641–42. http://dx.doi.org/10.1097/01.inf.0000223517.98486.2f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chapel, H. "Intravenous immunoglobulin therapy." QJM 89, no. 9 (September 1, 1996): 641–44. http://dx.doi.org/10.1093/qjmed/89.9.641.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gordon, David S. "Intravenous immunoglobulin therapy." American Journal of Medicine 83, no. 4 (October 1987): 52–56. http://dx.doi.org/10.1016/0002-9343(87)90551-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Phillips, Rebecca. "Intravenous Immunoglobulin Administration." Biology of Blood and Marrow Transplantation 20, no. 2 (February 2014): S306—S307. http://dx.doi.org/10.1016/j.bbmt.2013.12.531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dhar, Sandipan. "Intravenous immunoglobulin in dermatology." Indian Journal of Dermatology 54, no. 1 (2009): 77. http://dx.doi.org/10.4103/0019-5154.48996.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Raghavendra, S., Javeria Nooraine, and RajeshB Iyer. "Intravenous immunoglobulin induced meningoencephalitis." Neurology India 62, no. 1 (2014): 98. http://dx.doi.org/10.4103/0028-3886.128354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Foster, P. R., A. G. Welch, B. Cuthbertson, R. J. Perry, and R. V. McIntosh. "Immunoglobulin for intravenous use." Transfusion Medicine 7, no. 1 (March 1997): 67–69. http://dx.doi.org/10.1046/j.1365-3148.1997.d01-83.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Imbach, Paul, Silvio Barandun, Hans Cottier, Edouard Gugler, Alfred Hassig, Andreas Morell, Hanspeter Wagner, and Hansjurg Heiniger. "Immunomodulation by Intravenous Immunoglobulin." Journal of Pediatric Hematology/Oncology 12, no. 1 (1990): 134–40. http://dx.doi.org/10.1097/00043426-199022000-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Sacher, Ronald A. "Intravenous immunoglobulin consensus statement☆☆☆." Journal of Allergy and Clinical Immunology 108, no. 4 (October 2001): S139—S146. http://dx.doi.org/10.1067/mai.2001.118640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Khan, S., P. C. Doré, and W. A. C. Sewell. "Intravenous immunoglobulin-induced neutropenia." Pediatric Allergy and Immunology 21, no. 5 (April 7, 2009): 892–93. http://dx.doi.org/10.1111/j.1399-3038.2009.00885.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Meurer, Michael, and Gerald Messer. "Plasmapheresis and intravenous immunoglobulin." Dermatologic Therapy 15, no. 4 (December 2002): 333–39. http://dx.doi.org/10.1046/j.1529-8019.2002.01542.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Uniyal, Ravi, Ravindra Kumar Garg, Hardeep Singh Malhotra, Neeraj Kumar, and Shweta Pandey. "Intravenous versus subcutaneous immunoglobulin." Lancet Neurology 17, no. 5 (May 2018): 393. http://dx.doi.org/10.1016/s1474-4422(18)30106-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Shaw, W. L., and R. R. C. Stewart. "SAFETY OF INTRAVENOUS IMMUNOGLOBULIN." Lancet 329, no. 8538 (April 1987): 928. http://dx.doi.org/10.1016/s0140-6736(87)92908-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Chapel, H. M., and V. M. Brennan. "HOME INTRAVENOUS IMMUNOGLOBULIN THERAPY." Lancet 332, no. 8625 (December 1988): 1423. http://dx.doi.org/10.1016/s0140-6736(88)90614-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Levy, J. B. "Nephrotoxicity of intravenous immunoglobulin." QJM 93, no. 11 (November 1, 2000): 751–55. http://dx.doi.org/10.1093/qjmed/93.11.751.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Catharine, J., R. Scott-Moncrieff, and William J. Reagan. "Human intravenous immunoglobulin therapy." Seminars in Veterinary Medicine and Surgery: Small Animal 12, no. 3 (August 1997): 178–85. http://dx.doi.org/10.1016/s1096-2867(97)80031-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

SEWELL, W. "Immunomodulation by intravenous immunoglobulin." Molecular Immunology 35, no. 11-12 (August 1998): 782. http://dx.doi.org/10.1016/s0161-5890(98)90494-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Milgrom, Henry. "Shortage of Intravenous Immunoglobulin." Annals of Allergy, Asthma & Immunology 81, no. 2 (August 1998): 97–100. http://dx.doi.org/10.1016/s1081-1206(10)62792-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Gordon, David S. "Intravenous immunoglobulin: Historical perspective." American Journal of Medicine 83, no. 4 (October 1987): 1–3. http://dx.doi.org/10.1016/0002-9343(87)90543-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Eggleton, Alison. "Calculation skills: Intravenous immunoglobulin." Nurse Prescribing 12, no. 4 (April 11, 2014): 170–71. http://dx.doi.org/10.12968/npre.2014.12.4.170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Matsuura, Eiji, Kazuko Kobayashi, Katsumi Inoue, and Yehuda Shoenfeld. "Intravenous Immunoglobulin and Atherosclerosis." Clinical Reviews in Allergy & Immunology 29, no. 3 (2005): 311–20. http://dx.doi.org/10.1385/criai:29:3:311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Molina, Vered, Miri Blank, and Yehuda Shoenfeld. "Intravenous Immunoglobulin and Fibrosis." Clinical Reviews in Allergy & Immunology 29, no. 3 (2005): 321–26. http://dx.doi.org/10.1385/criai:29:3:321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Green, Aldona. "Intravenous Immunoglobulin For Neonates." MCN, The American Journal of Maternal/Child Nursing 16, no. 4 (July 1991): 208–11. http://dx.doi.org/10.1097/00005721-199107000-00011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Thornton, C. A. "Safety of Intravenous Immunoglobulin." Archives of Neurology 50, no. 2 (February 1, 1993): 135–36. http://dx.doi.org/10.1001/archneur.1993.00540020013009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Salcedo, J., S. Keates, C. Pothoulakis, M. Warny, I. Castagliuolo, J. T. LaMont, and C. P. Kelly. "Intravenous immunoglobulin therapy for severe Clostridium difficile colitis." Gut 41, no. 3 (September 1, 1997): 366–70. http://dx.doi.org/10.1136/gut.41.3.366.

Full text
Abstract:
Background—Many individuals have serum antibodies against Clostridium difficile toxins. Those with an impaired antitoxin response may be susceptible to recurrent, prolonged, or severe C difficile diarrhoea and colitis.Aims—To examine whether treatment with intravenous immunoglobulin might be effective in patients with severe pseudomembranous colitis unresponsive to standard antimicrobial therapy.Patients—Two patients with pseudomembranous colitis not responding to metronidazole and vancomycin were given normal pooled human immunoglobulin intravenously (200–300 mg/kg).Methods—Antibodies against C difficile toxins were measured in nine immunoglobulin preparations by ELISA and by cytotoxin neutralisation assay.Results—Both patients responded quickly as shown by resolution of diarrhoea, abdominal tenderness, and distension. All immunoglobulin preparations tested contained IgG against C difficile toxins A and B by ELISA and neutralised the cytotoxic activity of C difficile toxins in vitro at IgG concentrations of 0.4–1.6 mg/ml.Conclusion—Passive immunotherapy with intravenous immunoglobulin may be a useful addition to antibiotic therapy for severe, refractory C difficile colitis. IgG antitoxin is present in standard immunoglobulin preparations andC difficile toxin neutralising activity is evident at IgG concentrations which are readily achieved in the serum by intravenous immunoglobulin administration.
APA, Harvard, Vancouver, ISO, and other styles
29

Dağoğlu, T., F. Ovali, N. Samanci, and E. Bengisu. "High-Dose Intravenous Immunoglobulin Therapy for Rhesus Haemolytic Disease." Journal of International Medical Research 23, no. 4 (July 1995): 264–71. http://dx.doi.org/10.1177/030006059502300406.

Full text
Abstract:
Rhesus haemolytic disease is a continuing problem in the newborn especially in countries where the use of anti-D immunoglobulin is not prevalent. The fetuses may need intrauterine transfusions to prevent hydrops faetalis and they also may need exchange transfusions to treat the hyperbilirubinaemia that develops after birth. These interventions expose the baby to several blood donors, hence the risk of infection and exchange transfusions. This study was performed to test whether the use of high-dose intravenous immunoglobulin soon after the birth of these infants reduced the need for exchange transfusions. After randomization, intravenous immunoglobulin was given at a dose of 500 mg/kg to 22 infants in the treatment group. Nothing was given to the 19 controls. The number of exchange transfusions needed decreased significantly in the treatment group. No side-effects of intravenous immunoglobulins were seen.
APA, Harvard, Vancouver, ISO, and other styles
30

Vakhlayrskaya, S. S., M. N. Kostyleva, A. S. Botkina, E. S. Ilyina, E. K. Donyush, and I. V. Kondratenko. "PRACTICAL ASPECTS OF THE APPLICATION OF INTRAVENOUS IMMUNOGLOBULINS FOR INTRAVENOUS ADMINISTRATION IN VARIOUS PATHOLOGIES." Pediatria. Journal named after G.N. Speransky 100, no. 2 (April 12, 2021): 174–81. http://dx.doi.org/10.24110/0031-403x-2021-100-2-174-181.

Full text
Abstract:
Human intravenous immunoglobulin (IVIG) – a blood product prepared from the serum of many healthy donors, is the mainstay of therapy for treatment of primary immunodeficiencies, is increasingly used in various fields of medicine. The article reflects practical aspects of use of this group of drugs in a multidisciplinary pediatric hospital not only taking the therapy of defects of the immune system as an example, but also oncohematological, neurological, dermatological diseases, including orphan diseases. The modern data on the mechanisms of action of immunoglobulins, schemes of use for various pathologies are presented. The issues of safety of application, interchangeability of immunoglobulins from different manufacturers are considered.
APA, Harvard, Vancouver, ISO, and other styles
31

Zhang, Li, Qi-Fang Song, Jing-Jie Jin, Ping Huang, Zhou-Ping Wang, Xiao-Fei Xie, Xiao-Qiong Gu, Xue-Juan Gao, and Hong-Ling Jia. "Differential protein analysis of serum exosomes post-intravenous immunoglobulin therapy in patients with Kawasaki disease." Cardiology in the Young 27, no. 9 (August 14, 2017): 1786–96. http://dx.doi.org/10.1017/s1047951117001433.

Full text
Abstract:
AbstractBackgroundKawasaki disease, which is characterised by systemic vasculitides accompanied by acute fever, is regularly treated by intravenous immunoglobulin to avoid lesion formation in the coronary artery; however, the mechanism of intravenous immunoglobulin therapy is unclear. Hence, we aimed to analyse the global expression profile of serum exosomal proteins before and after administering intravenous immunoglobulin.MethodsTwo-dimensional electrophoresis coupled with mass spectrometry analysis was used to identify the differentially expressed proteome of serum exosomes in patients with Kawasaki disease before and after intravenous immunoglobulin therapy.ResultsOur analysis revealed 69 differential protein spots in the Kawasaki disease group with changes larger than 1.5-fold and 59 differential ones in patients after intravenous immunoglobulin therapy compared with the control group. Gene ontology analysis revealed that the acute-phase response disappeared, the functions of the complement system and innate immune response were enhanced, and the antibacterial humoral response pathway of corticosteroids and cardioprotection emerged after administration of intravenous immunoglobulin. Further, we showed that complement C3 and apolipoprotein A-IV levels increased before and decreased after intravenous immunoglobulin therapy and that the insulin-like growth factor-binding protein complex acid labile subunit displayed reverse alteration before and after intravenous immunoglobulin therapy. These observations might be potential indicators of intravenous immunoglobulin function.ConclusionsOur results show the differential proteomic profile of serum exosomes of patients with Kawasaki disease before and after intravenous immunoglobulin therapy, such as complement C3, apolipoprotein A-IV, and insulin-like growth factor-binding protein complex acid labile subunit. These results may be useful in the identification of markers for monitoring intravenous immunoglobulin therapy in patients with Kawasaki disease.
APA, Harvard, Vancouver, ISO, and other styles
32

Shehzad, Muzzamil, Tayyab Ali, Nusrat Bibi, and Shoaib Shafique. "A comprehensive review on preparation of pure immunoglobulins Authors." International Journal of Natural Medicine and Health Sciences 2, no. 1 (December 31, 2022): 48–55. http://dx.doi.org/10.52461/ijnms.v2i1.1372.

Full text
Abstract:
Immunoglobulins are also known as antibodies. Plasma cells are responsible for the production of immunoglobulins. Beta cells are activated against a pathogenic attack and facilitated the formation of different types of immunoglobulins naturally. These immunoglobulins are also artificially synthesized by non-specific laboratorial techniques include fractionation precipitation, electrophoretic methods, gel filtration chromatography, ion exchange chromatography, hydrophobic chromatography and by the specific immuno- adsorbent methods. Third generation immunoglobulins are effectively used for therapeutic purpose against viral infections intravenously. Second generation immunoglobulins synthesis involved removal of anti-complement contaminants and IgG aggregates, through enzymatic degradation and chemical modification. The harmful effects of intravenous immunoglobulins can be reduced by using ultraviolet light, P-propiolactone, and pepsin at pH 4. Intravenous immunoglobulin drugs lead to anti-inflammatory and immunomodulatory effects in various infections. The mechanism of action of intravenous immunoglobulins is dependent on the binding between the Fc portion of injected IgG and target cell receptors. Radiolabeling is performed by two methods as in vivo, in which radiolabeled antibodies are incorporated into the body to bind with the antibodies and in vitro method, radioactive material is bound with already formed antibodies. This chapter highlighted the artificial methods adopted for production of radiolabeled immunoglobulins holding significant therapeutic and diagnostic applications.
APA, Harvard, Vancouver, ISO, and other styles
33

Yang, Xi, Guiying Liu, Yaqian Huang, Stella Chen, Junbao Du, and Hongfang Jin. "A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease." Cardiology in the Young 25, no. 6 (January 19, 2015): 1182–90. http://dx.doi.org/10.1017/s1047951114002601.

Full text
Abstract:
AbstractObjectiveTo determine the optimal drug therapy for intravenous immunoglobulin-resistant Kawasaki disease.MethodsStudies regarding drug therapy for intravenous immunoglobulin-resistant Kawasaki disease were selected from medical electronic databases including PubMed, Medline, Elsevier, and Springer Link. The effectiveness in terms of temperature recovery and coronary artery damage was compared between a second intravenous immunoglobulin treatment and glucocorticosteroid treatment for children with intravenous immunoglobulin-resistant Kawasaki disease using meta-analysis with Review Manager 5.3 software. Indices to evaluate the effects were body temperature, biomarker levels, and coronary artery lesions detected by echocardiography. Results are reported as relative risks or odds ratio with a 95% confidence interval and p<0.05.ResultsMeta-analysis included 52 patients in the second intravenous immunoglobulin treatment group and 75 patients in the glucocorticosteroid treatment control group from four studies that met our inclusion criteria. Temperatures of patients who received glucocorticosteroid treatment were effectively controlled compared with those who received a second intravenous immunoglobulin treatment (relative risk=0.73, 95% confidence interval: 0.58–0.92, p=0.007). There were no differences, however, in the incidence of coronary artery lesions between the two groups (odds ratio=1.55, 95% confidence interval: 0.57–4.20, p=0.39).ConclusionsGlucocorticosteroids are more effective in controlling body temperature compared with intravenous immunoglobulin re-treatment in intravenous immunoglobulin-resistant Kawasaki disease children; however, glucocorticosteroids and intravenous immunoglobulin re-treatment showed no difference in the prevention of coronary artery lesions.
APA, Harvard, Vancouver, ISO, and other styles
34

Odani, Toshio, and Tetsuya Horita. "5. High Dose Intravenous Immunoglobulin." Nihon Naika Gakkai Zasshi 98, no. 10 (2009): 2512–17. http://dx.doi.org/10.2169/naika.98.2512.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Misbah, Siraj A., and Helen M. Chapel. "Adverse Effects of Intravenous Immunoglobulin." Drug Safety 9, no. 4 (October 1993): 254–62. http://dx.doi.org/10.2165/00002018-199309040-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Uemura, Yahiro, Kazuo Takechi, Yutaka Hirao, Kazumasa Yokoyama, Masayuki Nishida, and Tadakazu Suyama. "Heat treated intravenous immunoglobulin preparation." Journal of the Japan Society of Blood Transfusion 35, no. 3 (1989): 350–56. http://dx.doi.org/10.3925/jjtc1958.35.350.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Bell, Susan Givens. "Immunomodulation, Part III : Intravenous Immunoglobulin." Neonatal Network 25, no. 3 (May 2006): 213–21. http://dx.doi.org/10.1891/0730-0832.25.3.213.

Full text
Abstract:
SEPSIS CONTINUES TO BE A MAJOR cause of morbidity and mortality in the NICU. In a 2002 study of late-onset sepsis in very low birth weight (VLBW) infants, the National Institute of Child Health and Human Development Neonatal Research Network found that, of 6,215 infants who survived beyond three days, 1,313 (21 percent) experienced at least one episode of blood culture–proven sepsis. Not only does sepsis increase the length and cost of stay in the NICU, but VLBW neonates with sepsis are significantly more likely to die than are uninfected infants (18 percent versus 7 percent).1 The most recently published statistics on sepsis-related neonatal mortality reveal that early neonatal mortality from sepsis declined from an average of 24.9/100,000 live births between 1985 and 1991 to an average of 15.6/100,000 live births between 1995 and 1998. The rate of late neonatal mortality from sepsis increased from 14.8/100,000 live births between 1985 and 1991 to 16.2/100,000 live births between 1995 and 1998.2
APA, Harvard, Vancouver, ISO, and other styles
38

Tedla, Fasika M., Andrea Roche-Recinos, and Amarpali Brar. "Intravenous immunoglobulin in kidney transplantation." Current Opinion in Organ Transplantation 20, no. 6 (December 2015): 630–37. http://dx.doi.org/10.1097/mot.0000000000000250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

EL-SHANAWANY, T., and S. JOLLES. "Intravenous Immunoglobulin and Autoimmune Disease." Annals of the New York Academy of Sciences 1110, no. 1 (September 1, 2007): 507–15. http://dx.doi.org/10.1196/annals.1423.054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Bussel, James B. "Neonatal Uses of Intravenous Immunoglobulin." Journal of Pediatric Hematology/Oncology 12, no. 4 (1990): 505–9. http://dx.doi.org/10.1097/00043426-199024000-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Ng, S. K. B. "Intravenous immunoglobulin infusion causing pseudohyponatremia." Lupus 8, no. 6 (July 1999): 488–90. http://dx.doi.org/10.1177/096120339900800617.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Nielsen, H. "Immunoglobulin preparations for intravenous administration." Allergy 49, no. 2 (February 1994): 69–75. http://dx.doi.org/10.1111/j.1398-9995.1994.tb00802.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

&NA;, &NA;. "When Is Intravenous Immunoglobulin Appropriate?" AJN, American Journal of Nursing 91, no. 6 (June 1991): 61. http://dx.doi.org/10.1097/00000446-199106000-00023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Jolles, S., W. A. C. Sewell, and S. A. Misbah. "Clinical uses of intravenous immunoglobulin." Clinical and Experimental Immunology 142, no. 1 (October 2005): 1–11. http://dx.doi.org/10.1111/j.1365-2249.2005.02834.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Stewart, R. R. C., R. J. Winney, and J. D. Cash. "Renal Toxicity of Intravenous Immunoglobulin." Vox Sanguinis 65, no. 3 (1993): 244. http://dx.doi.org/10.1159/000462433.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Gibb, D., and M. Levin. "Intravenous immunoglobulin in HIV infection." Archives of Disease in Childhood 65, no. 2 (February 1, 1990): 247–48. http://dx.doi.org/10.1136/adc.65.2.247-c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Relkin, N. "Intravenous immunoglobulin for Alzheimer's disease." Clinical & Experimental Immunology 178 (December 2014): 27–29. http://dx.doi.org/10.1111/cei.12500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Kaveri, S. V., M. Lecerf, C. Saha, M. D. Kazatchkine, S. Lacroix-Desmazes, and J. Bayry. "Intravenous immunoglobulin and immune response." Clinical & Experimental Immunology 178 (December 2014): 94–96. http://dx.doi.org/10.1111/cei.12526.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

MELISH, MARIAN E. "Intravenous immunoglobulin in Kawasaki syndrome." Pediatric Infectious Disease Journal 5, no. 3 (May 1986): S216. http://dx.doi.org/10.1097/00006454-198605010-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Kreuter, A., S. Reich-Schupke, M. Stücker, P. Altmeyer, and T. Gambichler. "Intravenous immunoglobulin for pyoderma gangrenosum." British Journal of Dermatology 158, no. 4 (April 2008): 856–57. http://dx.doi.org/10.1111/j.1365-2133.2007.08433.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Intravenous Immunoglobulin' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography